FAERS Database Analysis Reveals Safety Profile of Imiglucerase in Gaucher Disease Treatment
Key Insights
A comprehensive analysis of 3,810 adverse event reports from the FAERS database spanning 2004-2023 identified significant safety signals for imiglucerase across multiple organ systems, with the highest number of reports in general disorders and administration site conditions.
The study revealed strong statistical signals for bone infarction (search) (ROR 316.62) and osteonecrosis (search), but comparative analysis with other Gaucher disease (search) therapies suggests these events reflect disease severity rather than drug-specific toxicity.
Researchers identified 101 preferred terms with high signal strength, including increased chitotriosidase (search) and acid phosphatase (search) levels, highlighting the need for vigilant monitoring of skeletal complications and biomarkers during enzyme replacement therapy.
A comprehensive pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database has revealed important insights into the safety profile of imiglucerase, a widely used enzyme replacement therapy for Gaucher disease (search). The study, spanning nearly two decades of data from 2004 to 2023, analyzed 3,810 unique adverse event reports to identify potential safety signals and provide guidance for clinical practice.
Comprehensive Database Analysis Reveals Temporal Trends
The analysis examined 166,800,135 adverse event reports from the FAERS database, with imiglucerase-related reports showing notable temporal variations. Annual reporting peaked in 2009 with 967 reports and declined to 364 reports in 2021, though a resurgence occurred in 2023 with 724 reports. The quarterly distribution revealed significant fluctuations, with the highest single-quarter reporting occurring in Q2 2008 with 286 reports.
Among the analyzed reports, female patients were significantly more represented than males, accounting for 51.97% and 36.33% respectively, with an average patient age of 33 years. The majority of reports were submitted by internists (46.25%) and consumers (33.18%), with the United States contributing 39.55% of reports with known origins.
Signal Detection Identifies Multiple Organ System Involvement
The study employed four established disproportionality analysis methods - Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS) - to ensure robust signal detection. At the System Organ Class level, the analysis revealed the highest number of reports in general disorders and administration site conditions (n=1,699), followed by injury, poisoning, and procedural complications (n=1,245).
In terms of signal strength, pregnancy, puerperium, and perinatal conditions showed the strongest association with ROR 3.1 (95% CI: 2.65, 3.62), followed by congenital, familial, and genetic disorders with ROR 2.41 (95% CI: 1.96, 2.97), and hepatobiliary disorders with ROR 2.08 (95% CI: 1.82, 2.37).
Skeletal Complications Emerge as Primary Concern
At the Preferred Term level, after excluding the methodologically expected signal for "Gaucher disease (search)" itself (ROR 6352.95), the analysis identified 101 clinically relevant signals. The most significant included increased chitotriosidase (search) with ROR 5077.83 (95% CI: 3014.21, 8554.28), increased acid phosphatase (search) with ROR 910.62 (95% CI: 376.98, 2199.65), and bone infarction (search) with ROR 316.62 (95% CI: 217.03, 461.93).
The musculoskeletal and connective tissue disorders category showed the highest number of reports (n=313), with common events including bone pain (search) (n=126) and osteonecrosis (search) (n=80). However, the most significant signal strengths were observed for bone infarction (search) and hip dysplasia (search) with ROR 46.56 (95% CI: 17.38, 124.75).
Comparative Analysis Provides Critical Context
To address potential confounding by indication, researchers conducted a comparative analysis with three other FDA-approved Gaucher disease (search) therapies: velaglucerase alfa, taliglucerase alfa, and eliglustat. This analysis revealed that bone infarction (search) signals were similarly strong for imiglucerase (ROR 316.62) and velaglucerase alfa (ROR 132.16), but absent for taliglucerase alfa and eliglustat.
This pattern suggests that the intense signal for bone infarction (search) reflects the severity of underlying Gaucher disease (search) rather than drug-specific toxicity. Patients prescribed imiglucerase or velaglucerase may represent a cohort with more severe disease phenotypes inherently at higher risk for skeletal complications, while those on substrate reduction therapy or plant cell-expressed enzymes may have less severe disease presentations.
Clinical Outcomes and Administration Patterns
The analysis revealed that the most common adverse events resulted in hospitalization or prolonged hospital stay (34.77% of reports), followed by death events (20.26%). Other significant outcomes included life-threatening conditions (2.67%) and disability (2.48%). The median duration of drug use was 1,117 days with an interquartile range of 246.50-3118.50 days, indicating substantial variation in treatment duration.
Regarding administration routes, the vast majority of cases involved intravenous injection (65.30%), consistent with the drug's approved administration method. This finding aligns with imiglucerase's requirement for intravenous administration, with dosage adjusted according to patient weight and disease severity.
Implications for Clinical Practice
The study's findings offer important guidance for clinicians managing Gaucher disease (search) patients. While the analysis detected signals for pregnancy, puerperium, and perinatal conditions, researchers emphasized that FAERS data has profound limitations for assessing materno-fetal risk due to the absence of denominators, significant reporting bias, and confounding by disease effects.
For skeletal health management, the results underscore the critical need for vigilant, ongoing monitoring throughout long-term therapy. The persistence of bone pain (search) and osteonecrosis (search) signals suggests these events represent manifestations of underlying disease rather than direct adverse drug reactions, emphasizing the importance of proactive skeletal management strategies.
The study also identified potential mechanisms underlying persistent disease manifestations during therapy, including immune-mediated responses. A subset of patients develops anti-drug antibodies that can significantly impair drug efficacy by binding to the enzyme and blocking its activity, leading to suboptimal substrate clearance and persistent Gaucher cell activity.
Database Stability and Study Limitations
The analysis confirmed the overall stability of FAERS data trends despite yearly fluctuations, providing a reliable foundation for long-term drug safety assessments. However, researchers acknowledged several limitations, including the inherent underreporting and reporting bias of spontaneous reporting systems, inability to control for important confounding variables such as concomitant medications, and the limitation that disproportionality analysis can only generate signals without establishing causality.
The study's comparative analysis approach provided significant methodological strength by offering evidence that severe skeletal signals are likely attributable to confounding by indication rather than direct drug toxicity. This finding has important implications for patient counseling and clinical monitoring strategies, shifting focus from drug safety concerns to the need for comprehensive disease management in high-risk patient populations.